Pharmacokinetics and estimated bioavailability of grapiprant, a novel selective prostaglandin E₂ receptor antagonist, after oral administration in fasted and fed dogs

References

• *Anonymous, Freedom of Information Summary. Original New Animal Drug Application, NADA 141-455. http://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM494127.pdf (accessed 9 September 2016). U.S. Food and Drug Administration, Silver Spring, MD, USA, 2016
   Google Scholar
• De Vito V, Saba A, Lee HK, Owen H, Poapolathep A, Giorgi M. Detection and quantification of the selective EP4 receptor antagonist CJ-023423 (grapiprant) in canine plasma by HPLC with spectrofluorimetric detection. Journal of Pharmaceutical and Biomedical Analysis 118, 251–58, 2015 doi: 10.1016/j.jpba.2015.11.004
   PubMed Web of Science ®Google Scholar
• Giorgi M. CJ-023,423 (Grapiprant) a potential novel active compound with antihyperalgetic properties for veterinary patients. American Journal of Animal and Veterinary Sciences 10, 53–6, 2015 doi: 10.3844/ajavsp.2015.53.56
   Google Scholar
• Kim TW, Giorgi M. A brief overview of the coxib drugs in the veterinary field. American Journal of Animal and Veterinary Sciences 8, 89–97, 2013 doi: 10.3844/ajavsp.2013.89.97
   Google Scholar
• Kirkby Shaw K, Rausch-Derra LC, Rodhes L. Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Veterinary Medicine and Science 2, 3–9, 2016 doi: 10.1002/vms3.13
   PubMed Web of Science ®Google Scholar
• KuKanich B, Bidgood T, Knesl O. Clinical pharmacology of nonsteroidal ant-inflammatory drugs in dogs. Veterinary Anaesthesia and Analgesia 39, 69–90, 2012 doi: 10.1111/j.1467-2995.2011.00675.x
   PubMed Web of Science ®Google Scholar
• Lee HK, De Vito V, Giorgi M. Soluble epoxide hydrolase inhibitors: new molecules with potential for use in veterinary medicine. Israel Journal of Veterinary Medicine 69, 55–61, 2015
   Web of Science ®Google Scholar
• Lin CR, Amaya F, Barrett L, Wang H, Takada J, Samad TA, Woolf CJ. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. Journal of Pharmacology and Experimental Therapeutics 319, 1096–103, 2006 doi: 10.1124/jpet.106.105569
   PubMed Web of Science ®Google Scholar
• Nakao K, Murase A, Ohshiro H, Okumura T, Taniguchi K, Murata Y, Masuda M, Kato T, Okumura Y, Takada J. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties. Journal of Pharmacology and Experimental Therapeutics 322, 686–94, 2007 doi: 10.1124/jpet.107.122010
   PubMed Web of Science ®Google Scholar
• Nagahisa A, Okumura T. Pharmacology of grapiprant, a novel EP4 antagonist: receptor binding, efficacy in a rodent post-operative pain model, and a dose estimation for controlling pain in dogs. Journal of Veterinary Pharmacology and Therapeutics doi:10.1111/jvp.12349, 2016
   PubMed Web of Science ®Google Scholar
• Rausch-Derra LC, Huebner M, Rhodes L. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritic pain and inflammation, in healthy dogs. American Journal of Veterinary Research, 76, 853–9, 2015 doi: 10.2460/ajvr.76.10.853
   PubMed Web of Science ®Google Scholar
• Rausch-Derra LC, Huebner M, Wofford J, Rhodes L. A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis. Journal of Veterinary Internal Medicine 30, 756–63, 2016a doi: 10.1111/jvim.13948
   PubMed Web of Science ®Google Scholar
• Rausch-Derra LC, Rhodes L, Freshwater L, Hawks R. Pharmacokinetic comparison of oral tablet and suspension formulations of grapiprant, a novel therapeutic for the pain and inflammation of osteoarthritis in dogs. Journal Veterinary Pharmacology and Therapeutics doi:10.1111/jvp.12306, 2016b
   Web of Science ®Google Scholar
• Toutain PL, Bousquet-Mélou A. Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics 27, 415–25, 2004a doi: 10.1111/j.1365-2885.2004.00605.x
   PubMed Web of Science ®Google Scholar
• Toutain PL, Bousquet-Mélou A. Plasma terminal half-life. Journal of Veterinary Pharmacology and Therapeutics 27, 427–439, 2004b doi: 10.1111/j.1365-2885.2004.00600.x
   PubMed Web of Science ®Google Scholar
• Toutain PL, Lees P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 27, 467–77, 2004 doi: 10.1111/j.1365-2885.2004.00613.x
   PubMed Web of Science ®Google Scholar
• Woodward DF, Jones RL, Narumiya S. International union of basic and clinical pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacological Reviews 63, 471–538, 2011 doi: 10.1124/pr.110.003517
   PubMed Web of Science ®Google Scholar